.svg){kind=logo}
.svg){kind=icon}
Article
Sublingual Interferon Alpha Project wins NHMRC Funding
December 20, 2011
Prof. Paul Hertzog of the Monash Institute of Medical Research, in collaboration with Medicines Development, has been awarded a $422,418 Development Grant by the Australian National Health and Medical Research Council (NHMRC) to develop sublingual (oral) interferon alpha for the treatment of viral hepatitis. Ninety-seven Development Grant applications were reviewed, with only 16 (16.5%) being funded to commence in 2012.
The NHMRC Development Grant Peer Review Panel stated that they were impressed by the strength and complementary nature of the proposed team, its strong interferon research background, and its expertise in the commercialisation of antivirals. The panel also agreed that sublingual interferon alpha has obvious advantages, a significant market value and addresses an unmet medical need.
Medicines Development’s successful NHMRC Development Grant is part of the $114.2 million investment in health and medical research announced by the Minister for Health, Tanya Plibersek.
REFERENCES
Stay up to date
Follow our work by signing up for our newsletter
MDGH respectfully acknowledges the Traditional Owners of the land on which our office is located, the Wurundjeri people of the Kulin Nation, and pay our respect to their Elders past, present and emerging.
Medicines Development for Global Health Limited.
Level 1, 18 Kavanagh Street Southbank Victoria 3006 Australia.
ABN: 79 116 977 523